Skip to main content
SpringerLink
Log in

Consequence of Energy Imbalance in Prostate Cancer and Comorbidities

  • Chapter
  • First Online:
Energy Balance and Prostate Cancer

Part of the book series: Energy Balance and Cancer ((EBAC,volume 14))

  • 344 Accesses

Abstract

Obesity and prostate cancer are two of the most common conditions in older men and there is strong evidence that obesity influences the risk, aggressiveness and outcomes of men with prostate cancer. In addition, several comorbidities are observed with obesity, including diabetes mellitus, hypertension, hypercholesterolemia and cardiovascular disease. Separate study of these diagnoses has also identified associations with prostate cancer risk and outcomes. Whether the underlying obesity, the comorbid conditions, or both are responsible for the observed interactions with prostate cancer is not fully understood. Further, pharmacologic treatment of these comorbidities may influence prostate cancer, either by reducing the direct effect of the comorbidity, or independently through additional pharmacologic mechanisms. In this chapter, we review the relationship between common obesity related comorbidities and prostate cancer risk, progression and mortality. We also describe, when available, data on the medications used to treat these comorbidities and the influence these therapies may have on prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38. doi:10.1056/NEJMoa021423.

    Article  PubMed  Google Scholar 

  2. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, Leitzmann MF. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007;109(4):675–84. doi:10.1002/cncr.22443.

    Article  PubMed  Google Scholar 

  3. Hsing AW, Sakoda LC, Chua S Jr. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86(3):s843–57.

    PubMed  Google Scholar 

  4. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013;63(5):800–9. doi:10.1016/j.eururo.2012.11.013.

    Article  CAS  PubMed  Google Scholar 

  5. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006;17(8):989–1003. doi:10.1007/s10552-006-0049-z.

    Article  PubMed  Google Scholar 

  6. Discacciati A, Orsini N, Wolk A. Body mass index and incidence of localized and advanced prostate cancer—a dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23(7):1665–71. doi:10.1093/annonc/mdr603.

    Article  CAS  PubMed  Google Scholar 

  7. Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J, Liu C, Guo H. Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies. Oncol Lett. 2015;9(3):1307–12. doi:10.3892/ol.2014.2841.

    PubMed  Google Scholar 

  8. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer. 2007;109(6):1192–202. doi:10.1002/cncr.22534.

    Article  PubMed  Google Scholar 

  9. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol. 1984;120(2):244–50.

    Article  CAS  PubMed  Google Scholar 

  10. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomark Prev. 2001;10(4):345–53.

    CAS  Google Scholar 

  11. Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, Zincke H, Blute ML. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer. 2006;107(3):521–9. doi:10.1002/cncr.22030.

    Article  PubMed  Google Scholar 

  12. Banez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009;182(2):491–496. discussion 6–8. doi:10.1016/j.juro.2009.04.007.

    Article  PubMed  Google Scholar 

  13. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007;110(12):2691–9. doi:10.1002/cncr.23093.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, Isaacs WB, Partin AW. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol. 2005;174(3):919–22. doi:10.1097/01.ju.0000169459.78982.d7.

    Article  PubMed  Google Scholar 

  15. Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B, Aronson WJ. Search Database Study G. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol. 2004;172(2):520–4. doi:10.1097/01.ju.0000135302.58378.ae.

    Article  PubMed  Google Scholar 

  16. Jayachandran J, Banez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ, Group SDS. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2009;115(22):5263–71. doi:10.1002/cncr.24571.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kane CJ, Im R, Amling CL, Presti JC Jr, Aronson WJ, Terris MK, Freedland SJ, Group SDS. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010;76(3):695–700. doi:10.1016/j.urology.2009.12.073.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Major JM, Klonoff-Cohen HS, Pierce JP, Slymen DJ, Saltzstein SL, Macera CA, Mercola D, Kattan MW. Prostate cancer postoperative nomogram scores and obesity. PLoS One. 2011;6(2):e17382. doi:10.1371/journal.pone.0017382.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, Babaian RJ, Troncoso P. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005;11(19 Pt 1):6889–94. doi:10.1158/1078-0432.CCR-04-1977.

    Article  CAS  PubMed  Google Scholar 

  20. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91. doi:10.1038/nrc1408.

    Article  CAS  PubMed  Google Scholar 

  21. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A, Nyren O. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst. 1997;89(5):385–9.

    Article  CAS  PubMed  Google Scholar 

  22. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039–47. doi:10.1016/S1470-2045(08)70235-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4(4):486–501. doi:10.1158/1940-6207.CAPR-10-0229.

    Article  CAS  Google Scholar 

  24. Demark-Wahnefried W, Platz EA, Ligibel JA, Blair CK, Courneya KS, Meyerhardt JA, Ganz PA, Rock CL, Schmitz KH, Wadden T, Philip EJ, Wolfe B, Gapstur SM, Ballard-Barbash R, McTiernan A, Minasian L, Nebeling L, Goodwin PJ. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomark Prev. 2012;21(8):1244–59. doi:10.1158/1055-9965.EPI-12-0485.

    Article  Google Scholar 

  25. Saydah S, Bullard KM, Cheng Y, Ali MK, Gregg EW, Geiss L, Imperatore G. Trends in cardiovascular disease risk factors by obesity level in adults in the United States, NHANES 1999–2010. Obesity (Silver Spring). 2014;22(8):1888–95. doi:10.1002/oby.20761.

    Article  CAS  Google Scholar 

  26. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart A, National Heart L, Blood I. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735–52. doi:10.1161/CIRCULATIONAHA.105.169404.

    Article  PubMed  Google Scholar 

  27. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539–53. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S.

  28. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb. 2005;12(6):295–300.

    Article  CAS  PubMed  Google Scholar 

  29. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–607.

    Article  CAS  PubMed  Google Scholar 

  30. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Rep. 2009(13):1–7.

    Google Scholar 

  31. Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006;164(8):769–74. doi:10.1093/aje/kwj284.

    Article  CAS  PubMed  Google Scholar 

  32. Tuohimaa P, Tenkanen L, Syvala H, Lumme S, Hakulinen T, Dillner J, Hakama M. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomark Prev. 2007;16(2):302–7. doi:10.1158/1055-9965.EPI-06-0777.

    Article  CAS  Google Scholar 

  33. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomark Prev. 2004;13(10):1646–50.

    CAS  Google Scholar 

  34. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, La Vecchia C. The metabolic syndrome and risk of prostate cancer in Italy. Ann Epidemiol. 2011;21(11):835–41. doi:10.1016/j.annepidem.2011.07.007.

    Article  PubMed  Google Scholar 

  35. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer. 2007;109(5):875–81. doi:10.1002/cncr.22461.

    Article  PubMed  Google Scholar 

  36. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, Jankowski M, Rybicki BA. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology. 2009;74(1):185–90. doi:10.1016/j.urology.2009.03.013.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006;164(11):1094–102. doi:10.1093/aje/kwj320.

    Article  PubMed  Google Scholar 

  38. Blanc-Lapierre A, Spence A, Karakiewicz PI, Aprikian A, Saad F, Parent ME. Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada. BMC Public Health. 2015;15:913. doi:10.1186/s12889-015-2260-x.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Sourbeer KN, Howard LE, Andriole GL, Moreira DM, Castro-Santamaria R, Freedland SJ, Vidal AC. Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. BJU Int. 2015;115(5):736–43. doi:10.1111/bju.12843.

    Article  CAS  PubMed  Google Scholar 

  40. Haggstrom C, Van Hemelrijck M, Zethelius B, Robinson D, Grundmark B, Holmberg L, Gudbjornsdottir S, Garmo H, Stattin P. Prospective study of Type 2 diabetes mellitus, anti-diabetic drugs and risk of prostate cancer. Int J Cancer. 2017;140(3):611–7. doi:10.1002/ijc.30480.

    Article  PubMed  CAS  Google Scholar 

  41. Lawrence YR, Morag O, Benderly M, Boyko V, Novikov I, Dicker AP, Goldbourt U, Behar S, Barchana M, Wolf I. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013;16(2):181–6. doi:10.1038/pcan.2012.54.

    CAS  PubMed  Google Scholar 

  42. Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, Sarma AV. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int. 2011;107(6):929–35. doi:10.1111/j.1464-410X.2010.09703.x.

    Article  PubMed  Google Scholar 

  43. Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44(2):293–7. doi:10.1016/j.ejca.2007.11.005.

    Article  PubMed  Google Scholar 

  44. Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, Tsugane S, Japan Public Health Center-based Prospective Study G. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18(3):240–7. doi:10.1097/CEJ.0b013e3283240460.

    Article  PubMed  Google Scholar 

  45. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control. 2009;20(7):1181–92. doi:10.1007/s10552-009-9319-x.

    Article  PubMed  Google Scholar 

  46. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Cancer Epidemiol Biomark Prev. 2010;19(8):2088–96. doi:10.1158/1055-9965.EPI-10-0112.

    Article  Google Scholar 

  47. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11. doi:10.2337/dc12-0336.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Xiang YZ, Xiong H, Cui ZL, Jiang SB, Xia QH, Zhao Y, Li GB, Jin XB. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res. 2013;32:9. doi:10.1186/1756-9966-32-9.

    Article  PubMed  PubMed Central  Google Scholar 

  49. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A, Tubaro A. Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate. 2011;71(14):1492–8. doi:10.1002/pros.21364.

    PubMed  Google Scholar 

  50. De Nunzio C, Simone G, Brassetti A, Mastroianni R, Collura D, Muto G, Gallucci M, Tubaro A. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer. 2016;16:407. doi:10.1186/s12885-016-2442-7.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Morote J, Ropero J, Planas J, Bastaros JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventos J, Doll A. Metabolic syndrome increases the risk of aggressive prostate cancer detection. BJU Int. 2013;111(7):1031–6. doi:10.1111/j.1464-410X.2012.11406.x.

    Article  CAS  PubMed  Google Scholar 

  52. Bhindi B, Locke J, Alibhai SM, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH, Fleshner NE. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015;67(1):64–70. doi:10.1016/j.eururo.2014.01.040.

    Article  CAS  PubMed  Google Scholar 

  53. Bhindi B, Xie WY, Kulkarni GS, Hamilton RJ, Nesbitt M, Finelli A, Zlotta AR, Evans A, van der Kwast TH, Alibhai SM, Trachtenberg J, Fleshner NE. Influence of metabolic syndrome on prostate cancer stage, grade, and overall recurrence risk in men undergoing radical prostatectomy. Urology. 2016;93:77–85. doi:10.1016/j.urology.2016.01.041.

    Article  PubMed  Google Scholar 

  54. Kheterpal E, Sammon JD, Diaz M, Bhandari A, Trinh QD, Pokala N, Sharma P, Menon M, Agarwal PK. Effect of metabolic syndrome on pathologic features of prostate cancer. Urol Oncol. 2013;31(7):1054–9. doi:10.1016/j.urolonc.2011.12.012.

    Article  PubMed  Google Scholar 

  55. Macleod LC, Chery LJ, Hu EY, Zeliadt SB, Holt SK, Lin DW, Porter MP, Gore JL, Wright JL. Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort. Prostate Cancer Prostatic Dis. 2015;18(2):190–5. doi:10.1038/pcan.2015.12.

    Article  CAS  PubMed  Google Scholar 

  56. Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, Blair SN. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer. 2009;45(10):1831–8. doi:10.1016/j.ejca.2009.01.031.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 2013;16(2):151–58. S1. doi:10.1038/pcan.2012.40.

    CAS  PubMed  Google Scholar 

  58. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47(6):1071–8. doi:10.1007/s00125-004-1415-6.

    Article  CAS  PubMed  Google Scholar 

  59. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomark Prev. 2006;15(11):2056–62. doi:10.1158/1055-9965.EPI-06-0410.

    Article  Google Scholar 

  60. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999–2002. Diabetes Care. 2006;29(6):1263–8. doi:10.2337/dc06-0062.

    Article  PubMed  Google Scholar 

  61. Calton BA, Chang SC, Wright ME, Kipnis V, Lawson K, Thompson FE, Subar AF, Mouw T, Campbell DS, Hurwitz P, Hollenbeck A, Schatzkin A, Leitzmann MF. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control. 2007;18(5):493–503. doi:10.1007/s10552-007-0126-y.

    Article  PubMed  Google Scholar 

  62. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol. 2009;169(8):937–45. doi:10.1093/aje/kwp003.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, Persson I. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2(5):307–14.

    Article  CAS  PubMed  Google Scholar 

  64. Tavani A, Gallus S, Bertuzzi M, Dal Maso L, Zucchetto A, Negri E, Franceschi S, Ramazzotti V, Montella M, La Vecchia C. Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol. 2005;47(3):313–317.; discussion 7. doi:10.1016/j.eururo.2004.10.027.

    Article  CAS  PubMed  Google Scholar 

  65. Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M, Sugawara Y, Ohmori-Matsuda K, Hozawa A, Nishino Y, Tsuji I. History of diabetes mellitus and the risk of prostate cancer: The Ohsaki Cohort Study. Cancer Causes Control. 2010;21(7):1025–32. doi:10.1007/s10552-010-9530-9.

    Article  PubMed  Google Scholar 

  66. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer. 2006;118(8):2105–9. doi:10.1002/ijc.21600.

    Article  CAS  PubMed  Google Scholar 

  67. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev. 2006;15(10):1977–83. doi:10.1158/1055-9965.EPI-06-0477.

    Article  Google Scholar 

  68. Rodriguez C, Patel AV, Mondul AM, Jacobs EJ, Thun MJ, Calle EE. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol. 2005;161(2):147–52. doi:10.1093/aje/kwh334.

    Article  PubMed  Google Scholar 

  69. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer. 2009;124(6):1398–403. doi:10.1002/ijc.24044.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control. 1998;9(1):3–9.

    Article  CAS  PubMed  Google Scholar 

  71. Fall K, Garmo H, Gudbjornsdottir S, Stattin P, Zethelius B. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomark Prev. 2013;22(6):1102–9. doi:10.1158/1055-9965.EPI-12-1046.

    Article  CAS  Google Scholar 

  72. Xu H, Jiang HW, Ding GX, Zhang H, Zhang LM, Mao SH, Ding Q. Diabetes mellitus and prostate cancer risk of different grade or stage: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2013;99(3):241–9. doi:10.1016/j.diabres.2012.12.003.

    Article  PubMed  Google Scholar 

  73. Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, Huang WY, Weiss JM, Danforth KN, Grubb RL 3rd, Andriole GL, Prostate LC. Ovarian Trial Project T. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008;19(10):1267–76. doi:10.1007/s10552-008-9198-6.

    Article  PubMed  Google Scholar 

  74. Tsilidis KK, Allen NE, Appleby PN, Rohrmann S, Nothlings U, Arriola L, Gunter MJ, Chajes V, Rinaldi S, Romieu I, Murphy N, Riboli E, Tzoulaki I, Kaaks R, Lukanova A, Boeing H, Pischon T, Dahm CC, Overvad K, Quiros JR, Fonseca-Nunes A, Molina-Montes E, Gavrila Chervase D, Ardanaz E, Khaw KT, Wareham NJ, Roswall N, Tjonneland A, Lagiou P, Trichopoulos D, Trichopoulou A, Palli D, Pala V, Tumino R, Vineis P, Bueno-de-Mesquita HB, Malm J, Orho-Melander M, Johansson M, Stattin P, Travis RC, Key TJ. Diabetes mellitus and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2015;136(2):372–81. doi:10.1002/ijc.28989.

    Article  CAS  PubMed  Google Scholar 

  75. Turner EL, Lane JA, Donovan JL, Davis MJ, Metcalfe C, Neal DE, Hamdy FC, Martin RM. Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). Int J Cancer. 2011;128(2):440–6. doi:10.1002/ijc.25360.

    Article  CAS  PubMed  Google Scholar 

  76. Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol. 2004;159(10):978–82.

    Article  CAS  PubMed  Google Scholar 

  77. Lee J, Giovannucci E, Jeon JY. Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springerplus. 2016;5(1):1548. doi:10.1186/s40064-016-3233-y.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Batty GD, Kivimaki M, Clarke R, Davey Smith G, Shipley MJ. Modifiable risk factors for prostate cancer mortality in London: forty years of follow-up in the Whitehall study. Cancer Causes Control. 2011;22(2):311–8. doi:10.1007/s10552-010-9691-6.

    Article  PubMed  Google Scholar 

  79. Best LG, Garcia-Esquinas E, Yeh JL, Yeh F, Zhang Y, Lee ET, Howard BV, Farley JH, Welty TK, Rhoades DA, Rhoades ER, Umans JG, Navas-Acien A. Association of diabetes and cancer mortality in American Indians: the Strong Heart Study. Cancer Causes Control. 2015;26(11):1551–60. doi:10.1007/s10552-015-0648-7.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Baradaran N, Ahmadi H, Salem S, Lotfi M, Jahani Y, Baradaran N, Mehrsai AR, Pourmand G. The protective effect of diabetes mellitus against prostate cancer: role of sex hormones. Prostate. 2009;69(16):1744–50. doi:10.1002/pros.21023.

    Article  CAS  PubMed  Google Scholar 

  81. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007;132(6):2208–25. doi:10.1053/j.gastro.2007.03.050.

    Article  CAS  PubMed  Google Scholar 

  82. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53(Suppl 3):S16–21.

    Article  CAS  PubMed  Google Scholar 

  83. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ. Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis. 2011;14(4):326–31. doi:10.1038/pcan.2011.28.

    Article  CAS  PubMed  Google Scholar 

  84. Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology. 1999;10(3):313–8.

    Article  CAS  PubMed  Google Scholar 

  85. Tseng CH. Diabetes and risk of prostate cancer: a study using the National Health Insurance. Diabetes Care. 2011;34(3):616–21. doi:10.2337/dc10-1640.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Tavani A, Gallus S, Bosetti C, Tzonou A, Lagiou P, Negri E, Trichopoulos D, La Vecchia C. Diabetes and the risk of prostate cancer. Eur J Cancer Prev. 2002;11(2):125–8.

    Article  CAS  PubMed  Google Scholar 

  87. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of U.S. veterans with diabetes. Int J Cancer. 2011;128(3):635–43. doi:10.1002/ijc.25362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hofmann U, Evans A, van der Kwast T, Trachtenberg J, Finelli A, Fleshner N, Sweet J, Pollak M. A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(3):252–8. doi:10.1038/pcan.2014.20.

    Article  CAS  PubMed  Google Scholar 

  89. Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–56. doi:10.1038/nrendo.2013.256.

    Article  CAS  PubMed  Google Scholar 

  90. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology. 2003;144(12):5179–83. doi:10.1210/en.2003-0982.

    Article  CAS  PubMed  Google Scholar 

  91. Hadad SM, Fleming S, Thompson AM. Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol. 2008;67(1):1–7. doi:10.1016/j.critrevonc.2008.01.007.

    Article  PubMed  Google Scholar 

  92. Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31–43. doi:10.1530/JME-12-0007.

    Article  CAS  PubMed  Google Scholar 

  93. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–28. doi:10.1038/nrc2536.

    Article  CAS  PubMed  Google Scholar 

  94. Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2012;2(9):778–90. doi:10.1158/2159-8290.CD-12-0263.

    Article  CAS  PubMed  Google Scholar 

  95. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des. 2007;13(7):671–86.

    Article  CAS  PubMed  Google Scholar 

  96. Wright JL, Plymate SR, Porter MP, Gore JL, Lin DW, Hu E, Zeliadt SB. Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer. Prostate Cancer Prostatic Dis. 2013;16(2):204–8. doi:10.1038/pcan.2013.5.

    CAS  PubMed  PubMed Central  Google Scholar 

  97. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol. 2002;20(1):42–51. doi:10.1200/JCO.2002.20.1.42.

    Article  CAS  PubMed  Google Scholar 

  98. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005;41(18):2887–95. doi:10.1016/j.ejca.2005.09.003.

    Article  CAS  PubMed  Google Scholar 

  99. Heni M, Hennenlotter J, Scharpf M, Lutz SZ, Schwentner C, Todenhofer T, Schilling D, Kuhs U, Gerber V, Machicao F, Staiger H, Haring HU, Stenzl A. Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer. PLoS One. 2012;7(12):e50953. doi:10.1371/journal.pone.0050953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Anwar MA, Kheir WA, Eid S, Fares J, Liu X, Eid AH, Eid AA. Colorectal and prostate cancer risk in diabetes: metformin, an actor behind the scene. J Cancer. 2014;5(9):736–44. doi:10.7150/jca.9726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–9. doi:10.1056/NEJM199602293340906.

    Article  CAS  PubMed  Google Scholar 

  102. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009;20(9):1617–22. doi:10.1007/s10552-009-9407-y.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol. 2008;168(8):925–31. doi:10.1093/aje/kwn190.

    Article  PubMed  Google Scholar 

  104. Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sorensen HT. Metformin use and prostate cancer risk. Eur Urol. 2014;66(6):1012–20. doi:10.1016/j.eururo.2014.04.027.

    Article  CAS  PubMed  Google Scholar 

  105. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5. doi:10.1136/bmj.38415.708634.F7.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Nordstrom T, Clements M, Karlsson R, Adolfsson J, Gronberg H. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer. 2015;51(6):725–33. doi:10.1016/j.ejca.2015.02.003.

    Article  PubMed  CAS  Google Scholar 

  107. Feng T, Sun X, Howard LE, Vidal AC, Gaines AR, Moreira DM, Castro-Santamaria R, Andriole GL, Freedland SJ. Metformin use and risk of prostate cancer: results from the REDUCE study. Cancer Prev Res (Phila). 2015;8(11):1055–60. doi:10.1158/1940-6207.CAPR-15-0141.

    Article  CAS  Google Scholar 

  108. Azoulay L, Dell’Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomark Prev. 2011;20(2):337–44. doi:10.1158/1055-9965.EPI-10-0940.

    Article  CAS  Google Scholar 

  109. Kowall B, Stang A, Rathmann W, Kostev K. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf. 2015;24(8):865–74. doi:10.1002/pds.3823.

    Article  CAS  PubMed  Google Scholar 

  110. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8(8):e71583. doi:10.1371/journal.pone.0071583.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013;37(3):207–18. doi:10.1016/j.canep.2012.12.009.

    Article  PubMed  CAS  Google Scholar 

  112. Yu H, Yin L, Jiang X, Sun X, Wu J, Tian H, Gao X, He X. Effect of metformin on cancer risk and treatment outcome of prostate cancer: a meta-analysis of epidemiological observational studies. PLoS One. 2014;9(12):e116327. doi:10.1371/journal.pone.0116327.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Stopsack KH, Ziehr DR, Rider JR, Giovannucci EL. Metformin and prostate cancer mortality: a meta-analysis. Cancer Causes Control. 2016;27(1):105–13. doi:10.1007/s10552-015-0687-0.

    Article  PubMed  Google Scholar 

  114. Raval AD, Thakker D, Vyas A, Salkini M, Madhavan S, Sambamoorthi U. Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2015;18(2):110–21. doi:10.1038/pcan.2014.52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184–95. doi:10.1093/annonc/mdw410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Deng D, Yang Y, Tang X, Skrip L, Qiu J, Wang Y, Zhang F. Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis. Diabetes Metab Res Rev. 2015;31(6):595–602. doi:10.1002/dmrr.2645.

    Article  CAS  PubMed  Google Scholar 

  117. Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2012;109(10):1495–502. doi:10.1111/j.1464-410X.2011.10555.x.

    Article  CAS  PubMed  Google Scholar 

  118. Chen YB, Chen Q, Wang Z, Zhou J. Insulin therapy and risk of prostate cancer: a systematic review and meta-analysis of observational studies. PLoS One. 2013;8(11):e81594. doi:10.1371/journal.pone.0081594.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  119. Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012;2012:413782. doi:10.1155/2012/413782.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  120. Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(4):349–57. doi:10.1111/dom.12036.

    Article  CAS  PubMed  Google Scholar 

  121. Onitilo AA, Stankowski RV, Berg RL, Engel JM, Glurich I, Williams GM, Doi SA. Type 2 diabetes mellitus, glycemic control, and cancer risk. Eur J Cancer Prev. 2014;23(2):134–40. doi:10.1097/CEJ.0b013e3283656394.

    Article  CAS  PubMed  Google Scholar 

  122. Hitron A, Adams V, Talbert J, Steinke D. The influence of antidiabetic medications on the development and progression of prostate cancer. Cancer Epidemiol. 2012;36(4):e243–50. doi:10.1016/j.canep.2012.02.005.

    Article  CAS  PubMed  Google Scholar 

  123. Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scand J Urol. 2017;51(1):5–12. doi:10.1080/21681805.2016.1271353.

    Article  CAS  PubMed  Google Scholar 

  124. Frohlich E, Wahl R. Chemotherapy and chemoprevention by thiazolidinediones. Biomed Res Int. 2015;2015:845340. doi:10.1155/2015/845340.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  125. Matsuyama M, Yoshimura R. Peroxisome proliferator-activated receptor-gamma is a potent target for prevention and treatment in human prostate and testicular cancer. PPAR Res. 2008;2008:249849. doi:10.1155/2008/249849.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  126. Erdmann E, Harding S, Lam H, Perez A. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab. 2016;18(3):266–73. doi:10.1111/dom.12608.

    Article  CAS  PubMed  Google Scholar 

  127. Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, Ehrlich SF, Mamtani R, Bilker W, Vaughn DJ, Nessel L, Van Den Eeden SK, Ferrara A. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314(3):265–77. doi:10.1001/jama.2015.7996.

    Article  CAS  PubMed  Google Scholar 

  128. Boxall N, Bennett D, Hunger M, Dolin P, Thompson PL. Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study. BMJ Open Diabetes Res Care. 2016;4(1):e000303. doi:10.1136/bmjdrc-2016-000303.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR, Investigators IT. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321–31. doi:10.1056/NEJMoa1506930.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer. 2008;123(7):1693–8. doi:10.1002/ijc.23715.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM Jr, Kristal AR. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev. 2009;18(11):2807–13. doi:10.1158/1055-9965.EPI-09-0472.

    Article  CAS  Google Scholar 

  132. Farwell WR, D’Avolio LW, Scranton RE, Lawler EV, Gaziano JM. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst. 2011;103(11):885–92. doi:10.1093/jnci/djr108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Shafique K, McLoone P, Qureshi K, Leung H, Hart C, Morrison DS. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years’ follow up. BMC Cancer. 2012;12:25. doi:10.1186/1471-2407-12-25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in the CLUE II cohort. Cancer Causes Control. 2010;21(1):61–8. doi:10.1007/s10552-009-9434-8.

    Article  PubMed  Google Scholar 

  135. Mondul AM, Weinstein SJ, Virtamo J, Albanes D. Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control. 2011;22(11):1545–52. doi:10.1007/s10552-011-9831-7.

    Article  PubMed  PubMed Central  Google Scholar 

  136. Kok DE, van Roermund JG, Aben KK, den Heijer M, Swinkels DW, Kampman E, Kiemeney LA. Blood lipid levels and prostate cancer risk; a cohort study. Prostate Cancer Prostatic Dis. 2011;14(4):340–5. doi:10.1038/pcan.2011.30.

    Article  CAS  PubMed  Google Scholar 

  137. Iso H, Ikeda A, Inoue M, Sato S, Tsugane S, Group JS. Serum cholesterol levels in relation to the incidence of cancer: the JPHC study cohorts. Int J Cancer. 2009;125(11):2679–86. doi:10.1002/ijc.24668.

    Article  CAS  PubMed  Google Scholar 

  138. Eichholzer M, Stahelin HB, Gutzwiller F, Ludin E, Bernasconi F. Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr. 2000;71(2):569–74.

    CAS  PubMed  Google Scholar 

  139. Wallace RB, Rost C, Burmeister LF, Pomrehn PR. Cancer incidence in humans: relationship to plasma lipids and relative weight. J Natl Cancer Inst. 1982;68(6):915–8.

    CAS  PubMed  Google Scholar 

  140. Chyou PH, Nomura AM, Stemmermann GN, Kato I. Prospective study of serum cholesterol and site-specific cancers. J Clin Epidemiol. 1992;45(3):287–92.

    Article  CAS  PubMed  Google Scholar 

  141. Hiatt RA, Fireman BH. Serum cholesterol and the incidence of cancer in a large cohort. J Chronic Dis. 1986;39(11):861–70.

    Article  CAS  PubMed  Google Scholar 

  142. Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomark Prev. 1995;4(8):807–11.

    CAS  Google Scholar 

  143. Knekt P, Reunanen A, Aromaa A, Heliovaara M, Hakulinen T, Hakama M. Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol. 1988;41(6):519–30.

    Article  CAS  PubMed  Google Scholar 

  144. Morris DL, Borhani NO, Fitzsimons E, Hardy RJ, Hawkins CM, Kraus JF, Labarthe DR, Mastbaum L, Payne GH. Serum cholesterol and cancer in the Hypertension Detection and Follow-up Program. Cancer. 1983;52(9):1754–9.

    Article  CAS  PubMed  Google Scholar 

  145. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J, Albanes D. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomark Prev. 2009;18(11):2814–21. doi:10.1158/1055-9965.EPI-08-1248.

    Article  CAS  Google Scholar 

  146. Kitahara CM, Berrington de Gonzalez A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592–8. doi:10.1200/JCO.2010.31.5200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Van Hemelrijck M, Garmo H, Holmberg L, Walldius G, Jungner I, Hammar N, Lambe M. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose. Cancer. 2011;117(10):2086–95. doi:10.1002/cncr.25758.

    Article  PubMed  CAS  Google Scholar 

  148. Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, Hayday A, Lambe M, Holmberg L. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control. 2011;22(7):1011–9. doi:10.1007/s10552-011-9774-z.

    Article  PubMed  Google Scholar 

  149. Gu Q, Paulose-Ram R, Burt VL, Kit BK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003–2012. NCHS Data Brief. 2014;177:1–8.

    Google Scholar 

  150. Moon H, Hill MM, Roberts MJ, Gardiner RA, Brown AJ. Statins: protectors or pretenders in prostate cancer? Trends Endocrinol Metab. 2014;25(4):188–96. doi:10.1016/j.tem.2013.12.007.

    Article  CAS  PubMed  Google Scholar 

  151. Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ. The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol. 2017;14(2):107–19. doi:10.1038/nrurol.2016.199.

    Article  CAS  PubMed  Google Scholar 

  152. Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7(10):e46691. doi:10.1371/journal.pone.0046691.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Lustman A, Nakar S, Cohen AD, Vinker S. Statin use and incident prostate cancer risk: does the statin brand matter? A population-based cohort study. Prostate Cancer Prostatic Dis. 2014;17(1):6–9. doi:10.1038/pcan.2013.34.

    Article  CAS  PubMed  Google Scholar 

  154. Jespersen CG, Norgaard M, Friis S, Skriver C, Borre M. Statin use and risk of prostate cancer: a Danish population-based case-control study, 1997–2010. Cancer Epidemiol. 2014;38(1):42–7. doi:10.1016/j.canep.2013.10.010.

    Article  PubMed  Google Scholar 

  155. Kantor ED, Lipworth L, Fowke JH, Giovannucci EL, Mucci LA, Signorello LB. Statin use and risk of prostate cancer: results from the Southern Community Cohort Study. Prostate. 2015;75(13):1384–93. doi:10.1002/pros.23019.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Freedland SJ, Hamilton RJ, Gerber L, Banez LL, Moreira DM, Andriole GL, Rittmaster RS. Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2013;16(3):254–9. doi:10.1038/pcan.2013.10.

    Article  CAS  PubMed  Google Scholar 

  157. Platz EA, Tangen CM, Goodman PJ, Till C, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Lucia MS, Thompson IM Jr, Kristal AR. Statin drug use is not associated with prostate cancer risk in men who are regularly screened. J Urol. 2014;192(2):379–84. doi:10.1016/j.juro.2014.01.095.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Chan JM, Litwack-Harrison S, Bauer SR, Daniels NA, Wilt TJ, Shannon J, Bauer DC. Statin use and risk of prostate cancer in the prospective Osteoporotic Fractures in Men (MrOS) Study. Cancer Epidemiol Biomark Prev. 2012;21(10):1886–8. doi:10.1158/1055-9965.EPI-12-0816.

    Article  Google Scholar 

  159. Tan P, Wei S, Yang L, Tang Z, Cao D, Liu L, Lei J, Fan Y, Gao L, Wei Q. The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis. Sci Rep. 2016;6:29106. doi:10.1038/srep29106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Meng Y, Liao YB, Xu P, Wei WR, Wang J. Statin use and mortality of patients with prostate cancer: a meta-analysis. Onco Targets Ther. 2016;9:1689–96. doi:10.2147/OTT.S97993.

    PubMed  PubMed Central  Google Scholar 

  161. Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL, Mostaghel EA. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomark Prev. 2011;20(4):619–27. doi:10.1158/1055-9965.EPI-10-1023.

    Article  CAS  Google Scholar 

  162. Mostaghel E, Nelson PS, Nelson C, Montgomery RB. Intraprostatic steroidogenic enzymes—letter. Cancer Res. 2010;70(20):8247–8249.; author reply 9–50. doi:10.1158/0008-5472.CAN-10-1458.

    Article  CAS  PubMed  Google Scholar 

  163. Harshman LC. Mind the gap: what is driving the survival disparity between the sexes in bladder cancer? Cancer. 2016;122(13):1966–70. doi:10.1002/cncr.30027.

    Article  PubMed  Google Scholar 

  164. Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GS, Kantoff PW. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1(4):495–504. doi:10.1001/jamaoncol.2015.0829.

    Article  PubMed  PubMed Central  Google Scholar 

  165. Boegemann M, Schlack K, Fischer AK, Gerss J, Steinestel J, Semjonow A, Schrader AJ, Krabbe LM. Influence of statins on survival outcome in patients with metastatic castration resistant prostate cancer treated with abiraterone acetate. PLoS One. 2016;11(9):e0161959. doi:10.1371/journal.pone.0161959.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  166. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol. 2001;11(8):534–42.

    Article  CAS  PubMed  Google Scholar 

  167. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME, Shapiro S. Calcium channel blockers and the risk of cancer. JAMA. 1998;279(13):1000–4.

    Article  CAS  PubMed  Google Scholar 

  168. Lindgren AM, Nissinen AM, Tuomilehto JO, Pukkala E. Cancer pattern among hypertensive patients in North Karelia. Finland J Hum Hypertens. 2005;19(5):373–9. doi:10.1038/sj.jhh.1001834.

    Article  CAS  PubMed  Google Scholar 

  169. Friedman GD. Blood pressure and heart rate: no evidence for a positive association with prostate cancer. Ann Epidemiol. 1997;7(7):486–9.

    Article  CAS  PubMed  Google Scholar 

  170. Hole DJ, Hawthorne VM, Isles CG, McGhee SM, Robertson JW, Gillis CR, Wapshaw JA,Lever AF. Incidence of and mortality from cancer in hypertensive patients. BMJ. 1993;306(6878):609–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Batty GD, Shipley MJ, Marmot MG, Davey Smith G, Whitehall S. Blood pressure and site-specific cancer mortality: evidence from the original Whitehall study. Br J Cancer. 2003;89(7):1243–7. doi:10.1038/sj.bjc.6601255.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Martin RM, Vatten L, Gunnell D, Romundstad P. Blood pressure and risk of prostate cancer: Cohort Norway (CONOR). Cancer Causes Control. 2010;21(3):463–72. doi:10.1007/s10552-009-9477-x.

    Article  PubMed  Google Scholar 

  173. Pai PY, Hsieh VC, Wang CB, Wu HC, Liang WM, Chang YJ, Wu TN. Long term antihypertensive drug use and prostate cancer risk: a 9-year population-based cohort analysis. Int J Cardiol. 2015;193:1–7. doi:10.1016/j.ijcard.2015.05.042.

    Article  PubMed  Google Scholar 

  174. Stocks T, Hergens MP, Englund A, Ye W, Stattin P. Blood pressure, body size and prostate cancer risk in the Swedish Construction Workers cohort. Int J Cancer. 2010;127(7):1660–8. doi:10.1002/ijc.25171.

    Article  CAS  PubMed  Google Scholar 

  175. Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS, Entschladen F. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer. 2006;118(11):2744–9. doi:10.1002/ijc.21723.

    Article  CAS  PubMed  Google Scholar 

  176. Ronquist G, Rodriguez LA, Ruigomez A, Johansson S, Wallander MA, Frithz G, Svardsudd K. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate. 2004;58(1):50–6. doi:10.1002/pros.10294.

    Article  CAS  PubMed  Google Scholar 

  177. Rodriguez C, Jacobs EJ, Deka A, Patel AV, Bain EB, Thun MJ, Calle EE. Use of blood-pressure-lowering medication and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control. 2009;20(5):671–9. doi:10.1007/s10552-008-9280-0.

    Article  PubMed  Google Scholar 

  178. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer. 2001;92(9):2462–70.

    Article  CAS  PubMed  Google Scholar 

  179. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B, de Faire U, Forsen K, Hedner T, Linjer E, Schersten B, Wester P, Moller T. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet. 2001;358(9281):539–44.

    Article  CAS  PubMed  Google Scholar 

  180. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 2004;15(6):535–41. doi:10.1023/B:CACO.0000036152.58271.5e.

    Article  PubMed  Google Scholar 

  181. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352(9123):179–84. doi:10.1016/S0140-6736(98)03228-0.

    Article  CAS  PubMed  Google Scholar 

  182. Morote J, Planas J. Antihypertensive drugs and the risk of prostate cancer. Eur Urol. 2011;60(6):1309–10. doi:10.1016/j.eururo.2011.09.009.

    Article  PubMed  Google Scholar 

  183. Vezina RM, Lesko SM, Rosenberg L, Shapiro S. Calcium channel blocker use and the risk of prostate cancer. Am J Hypertens. 1998;11(12):1420–5.

    Article  CAS  PubMed  Google Scholar 

  184. Kemppainen KJ, Tammela TL, Auvinen A, Murtola TJ. The association between antihypertensive drug use and incidence of prostate cancer in Finland: a population-based case-control study. Cancer Causes Control. 2011;22(10):1445–52. doi:10.1007/s10552-011-9819-3.

    Article  PubMed  Google Scholar 

  185. Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ. 2011;183(14):E1073–84. doi:10.1503/cmaj.101497.

    Article  PubMed  PubMed Central  Google Scholar 

  186. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627–36. doi:10.1016/S1470-2045(10)70106-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Collaboration ARBT. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011;29(4):623–35. doi:10.1097/HJH.0b013e328344a7de.

    Article  CAS  Google Scholar 

  188. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, Wallace RB, Havlik RJ. Calcium-channel blockade and incidence of cancer in aged populations. Lancet. 1996;348(9026):493–7. doi:10.1016/S0140-6736(96)04277-8.

    Article  CAS  PubMed  Google Scholar 

  189. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet. 1997;349(9051):525–8. doi:10.1016/S0140-6736(97)80084-0.

    Article  CAS  PubMed  Google Scholar 

  190. Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK, Baron JA. Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer. 2000;89(1):165–70.

    Article  CAS  PubMed  Google Scholar 

  191. Debes JD, Roberts RO, Jacobson DJ, Girman CJ, Lieber MM, Tindall DJ, Jacobsen SJ. Inverse association between prostate cancer and the use of calcium channel blockers. Cancer Epidemiol Biomark Prev. 2004;13(2):255–9.

    Article  CAS  Google Scholar 

  192. Thomas JA 2nd, Gerber L, Banez LL, Moreira DM, Rittmaster RS, Andriole GL, Freedland SJ. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomark Prev. 2012;21(4):576–81. doi:10.1158/1055-9965.EPI-11-1017.

    Article  CAS  Google Scholar 

  193. Lin H, Juang JL, Wang PS. Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis. J Biol Chem. 2004;279(28):29302–7. doi:10.1074/jbc.M403664200.

    Article  CAS  PubMed  Google Scholar 

  194. Stoffer SS, Hynes KM, Jiang NS, Ryan RJ. Digoxin and abnormal serum hormone levels. JAMA. 1973;225(13):1643–4.

    Article  CAS  PubMed  Google Scholar 

  195. Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008;8(1):36–49. doi:10.1124/mi.8.1.8.

    Article  CAS  PubMed  Google Scholar 

  196. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulate Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. Cancer Res. 2000;60(14):3807–12.

    CAS  PubMed  Google Scholar 

  197. Yeh JY, Huang WJ, Kan SF, Wang PS. Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. J Urol. 2001;166(5):1937–42.

    Article  CAS  PubMed  Google Scholar 

  198. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA. 2008;105(50):19579–86. doi:10.1073/pnas.0809763105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  199. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E, Nelson WG. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. 2011;1(1):68–77. doi:10.1158/2159-8274.CD-10-0020.

    Article  CAS  PubMed  Google Scholar 

  200. Wright JL, Hansten PD, Stanford JL. Is digoxin use for cardiovascular disease associated with risk of prostate cancer? Prostate. 2014;74(1):97–102. doi:10.1002/pros.22733.

    Article  CAS  PubMed  Google Scholar 

  201. Kaapu KJ, Murtola TJ, Maattanen L, Talala K, Taari K, Tammela TL,Auvinen A. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial. Cancer Causes Control. 2016;27(2):157–64. doi:10.1007/s10552-015-0693-2.

    Article  PubMed  Google Scholar 

  202. Karasneh RA, Murray LJ, Hughes CM, Cardwell CR. Digoxin use after diagnosis of prostate cancer and survival: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2016;25(9):1099–103. doi:10.1002/pds.4018.

    Article  CAS  PubMed  Google Scholar 

  203. Flahavan EM, Sharp L, Bennett K, Barron TI. A cohort study of digoxin exposure and mortality in men with prostate cancer. BJU Int. 2014;113(2):236–45. doi:10.1111/bju.12287.

    Article  CAS  PubMed  Google Scholar 

  204. Kaapu KJ, Ahti J, Tammela TL, Auvinen A, Murtola TJ. Sotalol, but not digoxin is associated with decreased prostate cancer risk: a population-based case-control study. Int J Cancer. 2015;137(5):1187–95. doi:10.1002/ijc.29470.

    Article  CAS  PubMed  Google Scholar 

  205. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136(2):161–72.

    Article  CAS  PubMed  Google Scholar 

  206. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000;275(15):11397–403.

    Article  CAS  PubMed  Google Scholar 

  207. Kirschenbaum A, Liu X, Yao S, Levine AC. The role of cyclooxygenase-2 in prostate cancer. Urology. 2001;58(2 Suppl 1):127–31.

    Article  CAS  PubMed  Google Scholar 

  208. Liu Y, Chen JQ, Xie L, Wang J, Li T, He Y, Gao Y, Qin X, Li S. Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. BMC Med. 2014;12:55. doi:10.1186/1741-7015-12-55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  209. Wright JL, Chery L, Holt S, Lin DW, Luedeke M, Rinckleb AE, Maier C, Stanford JL. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status. Prostate Cancer Prostatic Dis. 2016;19(1):53–6. doi:10.1038/pcan.2015.49.

    Article  CAS  PubMed  Google Scholar 

  210. Pierce BL, Plymate S, Ostrander EA, Stanford JL. Diabetes mellitus and prostate cancer risk. Prostate. 2008;68(10):1126–32. doi:10.1002/pros.20777.

    Article  PubMed  Google Scholar 

  211. Fukui M, Tanaka M, Kadono M, Imai S, Hasegawa G, Yoshikawa T, Nakamura N. Serum prostate-specific antigen levels in men with type 2 diabetes. Diabetes Care. 2008;31(5):930–1. doi:10.2337/dc07-1962.

    Article  CAS  PubMed  Google Scholar 

  212. Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. Association of diabetes and body mass index with levels of prostate-specific antigen: implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomark Prev. 2009;18(5):1350–6. doi:10.1158/1055-9965.EPI-08-0794.

    Article  Google Scholar 

  213. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001–2002. Am J Epidemiol. 2006;164(10):978–83. doi:10.1093/aje/kwj311.

    Article  PubMed  Google Scholar 

  214. Fowke JH, Motley SS, Cookson MS, Concepcion R, Chang SS, Wills ML, Smith JA Jr. The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis. 2007;10(2):137–42. doi:10.1038/sj.pcan.4500924.

    Article  CAS  PubMed  Google Scholar 

  215. Jayalath VH, Ireland C, Fleshner NE, Hamilton RJ, Jenkins DJ. The relationship between metformin and serum prostate-specific antigen levels. Prostate. 2016;76(15):1445–53. doi:10.1002/pros.23228.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  216. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, Wener M. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001–2004. Cancer Epidemiol Biomark Prev. 2007;16(1):70–6. doi:10.1158/1055-9965.EPI-06-0588.

    Article  CAS  Google Scholar 

  217. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298(19):2275–80. doi:10.1001/jama.298.19.2275.

    Article  PubMed  Google Scholar 

  218. Culp S, Porter M. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men. BJU Int. 2009;104(10):1457–61. doi:10.1111/j.1464-410X.2009.08646.x.

    Article  PubMed  Google Scholar 

  219. Hekal IA, Ibrahiem EI. Obesity-PSA relationship: a new formula. Prostate Cancer Prostatic Dis. 2010;13(2):186–90. doi:10.1038/pcan.2009.53.

    Article  CAS  PubMed  Google Scholar 

  220. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst. 2008;100(21):1511–8. doi:10.1093/jnci/djn362.

    Article  CAS  PubMed  Google Scholar 

  221. Wright JL, Lin DW, Stanford JL. The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate. 2011;71(15):1631–7. doi:10.1002/pros.21380.

    Article  PubMed  PubMed Central  Google Scholar 

  222. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, Group RS. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202. doi:10.1056/NEJMoa0908127.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Prevention Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N., M4-B402, Seattle, WA, 98109-1024, USA

    Jeannette M. Schenk PhD, RD

  2. Department of Urology, University of Washington, 1959 NE Pacific Street, Box 356510, Seattle, WA, 98195, USA

    Jonathan L. Wright MD, MS, FACS

  3. Epidemiology Program, Fred Hutchinson Cancer Research Center, 1100 Fariview Ave N., M4-A402, Seattle, WA, 98109-1024, USA

    Jonathan L. Wright MD, MS, FACS

Authors
  1. Jeannette M. Schenk PhD, RD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan L. Wright MD, MS, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan L. Wright MD, MS, FACS .

Editor information

Editors and Affiliations

  1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

    Elizabeth A. Platz

  2. Center for Science, Health and Society, Case Western Reserve University, Cleveland, Ohio, USA

    Nathan A. Berger

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Schenk, J.M., Wright, J.L. (2018). Consequence of Energy Imbalance in Prostate Cancer and Comorbidities. In: Platz, E., Berger, N. (eds) Energy Balance and Prostate Cancer. Energy Balance and Cancer, vol 14. Springer, Cham. https://doi.org/10.1007/978-3-319-64940-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64940-5_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64939-9

  • Online ISBN: 978-3-319-64940-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation